Background {#Sec1}
==========

Deep vein thrombosis (DVT) is one of the most common complications after lower extremity orthopedic surgery, several patients may develop into pulmonary embolism (PE), and some serious can lead to death \[[@CR1], [@CR2]\]. A large number of researches show that patients undergoing lower extremity orthopedic surgery are the high-risk group for venous thromboembolism (VTE). In the absence of any preventive measures, the incidence of DVT after surgery was up to 40--60%, the incidence of PE was 20%, and the fatal PE was 0.1--2% \[[@CR1]\]. Thus, guidelines for the prevention of postoperative anticoagulation have been recommended in various countries after excluding the contraindication \[[@CR1]--[@CR6]\].

Traditional Chinese medicine theory holds that DVT is the category of "pulse closed" and "femoral swelling," and the main treatment is to promote blood circulation to remove blood stasis. Traditional Chinese herb not only has the effects of analgesic and anti-inflammatory, but also can effectively improve blood circulation \[[@CR7]\]. Thus, in conducting the traditional Chinese medicine syndrome differentiation, adjuvant therapy on the basis of western medicine treatment is paying more attention to the theory of traditional Chinese medicine that diagnosis and treatment are based on an overall analysis of the illness and the patient's condition and also insisting on treating both principal and secondary aspect of disease. Therefore, the advantages of the combination of traditional Chinese and western medicine are becoming more and more prominent in the treatment and prevention of thrombotic diseases.

Although there is a long history of traditional Chinese medicine for prevention and treatment of DVT in ancient China, the necessary quantitative evidence to estimate treatment effects is still lacking. Therefore, we conducted this meta-analysis to evaluate the efficacy and safety of RCTs involving traditional Chinese and western medicine for the prevention of DVT after lower extremity orthopedic surgery, expecting to provide evidence-based medical proof for clinical medicine.

Methods {#Sec2}
=======

Search strategy {#Sec3}
---------------

A comprehensive search for studies about traditional Chinese and western medicine for the prevention of DVT after lower extremity orthopedic surgery was conducted through the online database. We searched PubMed, Cochrane Library, Web of knowledge, the Chinese National Knowledge Infrastructure Database, the Chongqing VIP Database, the Chinese Biomedical Database, and the Wanfang Database (including three English and four Chinese databases) up to May 31, 2017. The following keywords were used: ("traditional Chinese and western medicine" or "traditional Chinese medicine" or "Chinese herbal medicine" or "Chinese herb") in combination with (("lower extremity orthopedic surgery" or "arthroplasty" or "joint replacement" or "fracture") and ("deep venous thrombosis" or "Venous thromboembolism")). Additional studies were identified from references of retrieved articles. The duplicated articles were eliminated using Endnote software (EndNote X7).

Inclusion and exclusion criteria {#Sec4}
--------------------------------

Trials were eligible if they were randomized controlled trials (RCTs) recruiting participants with lower extremity orthopedic surgery (including total hip replacement \[THR\], total knee replacement \[TKR\], or hip fracture surgery \[HFS\]) and so on). These included patients in the experimental group who received the treatment of traditional Chinese and western medicine for the prevention of DVT after orthopedic surgery, while those in the control group were subjected to standard western therapy for DVT. All studies cited could provide relevant data. There was no language restriction in the literature search.

In order to evaluate the independent effects of the traditional Chinese and western medicine intervention, we excluded (1) conference abstracts, review articles, animal studies, cadaveric studies, in vitro studies, or articles published in a form other than clinical trials; (2) any control group that included traditional Chinese therapies; (3) literatures without relevant postoperative indicators or quantitative data; and (4) repeated published literature.

Selection of studies {#Sec5}
--------------------

Two authors (Zhu and Song) independently screened all potential eligible studies. Titles and abstracts were first screened to exclude irrelevant citations. Full text of all articles of potentially relevant abstracts were retrieved and screened according to the study inclusion and exclusion criteria.

Data extraction {#Sec6}
---------------

The two investigators (Zhu and Qian) reviewed the titles and abstracts, carefully read the full texts according to preset inclusion criteria, and extracted the data from included studies using a pre-designed data extraction table. Study characteristics that were extracted included the author, publication year, sample size, age and gender of subjects, and detailed information of two groups, outcome measures, summary of results, main conclusion, and adverse reactions. The data were arranged into experimental form and Excel spreadsheets in duplicate. All data extraction work was done by the two authors independently. When any inconsistency arose, the issues were either resolved by a third investigator (Chen) or negotiated by both the original investigators.

Definition of outcome events {#Sec7}
----------------------------

The main outcome events were the incidence of DVT, the outcomes of [d]{.smallcaps}-dimer, prothrombin time (PT), and thromboplastin time (APTT). The secondary events were any adverse events (including hematoma, hemorrhage, and so on) and other reported outcomes.

Quality assessment {#Sec8}
------------------

Two reviewers (Zhu and Song) independently conducted the methodological quality of all included studies. The cases were reviewed and screened carefully for data of interest. Any disagreement between the investigators was resolved with mutual consensus in the presence of the third author (Chen). The quality of studies was estimated according to the Newcastle-Ottawa Scale (NOS) \[[@CR8]\].

Statistical method {#Sec9}
------------------

For each included study, the weighted mean differences (WMD) at 95% confidence intervals (CI) were calculated for continuous outcomes, while odds ratio (OR) at 95% confidence intervals (CI) were calculated for dichotomous outcomes. Heterogeneity among the studies was assessed using the chi-squared and *I*-squared (*I*^2^) tests. A fixed effect model was applied when *I*^2^ \< 50%, whereas a random effect model was applied when *I*^2^ \> 50%. All analyses were completed with Review Manager 5.2 \[[@CR9], [@CR10]\] software (Cochrane Collaboration, Oxford, UK) and a *P* value \< 0.05 was considered statistically significant. Funnel plots were used to assess potential bias \[[@CR11]\].

Results {#Sec10}
=======

The flow of study identification and inclusion are shown in Fig. [1](#Fig1){ref-type="fig"}. In summary, a total of 520 abstracts identified from online databases (including three English and four Chinese databases). After initially screening 129 potentially relevant abstracts, we excluded 75 because they did not meet the inclusion criteria (reviews, case reports, or duplicate publications). We retrieved and reviewed 54 full articles; 34 were excluded due to lack of randomization or absence of a control group (*n* = 15), major methodologic flaws, and insufficient data (*n* = 19). Finally, 20 eligible RCTs \[[@CR12]--[@CR31]\] involving 1862 patients were included.Fig. 1Flow diagram of searches

Basic characteristics of included studies {#Sec11}
-----------------------------------------

The characteristics of the 20 RCTs are summarized in Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"}, [3](#Tab3){ref-type="table"}, [4](#Tab4){ref-type="table"}, [5](#Tab5){ref-type="table"}, and [6](#Tab6){ref-type="table"}. All 20 RCTs were conducted in China and were published between 2006 and 2017. There are a total of 910 participants who received traditional Chinese and western medicine (experimental group) and 952 who received standard western treatment (control group). All 20 papers reported the incidence rate of DVT after lower extremity orthopedic surgery, 9 papers had data on [d]{.smallcaps}-dimer, 8 papers had the outcomes of PT and APTT, and 4 papers reported subcutaneous hematoma. All papers had similar distributions of sex, age, and types of surgery. The included studies are described in Table [1](#Tab1){ref-type="table"}. Table [2](#Tab2){ref-type="table"} includes the composition and efficacy of traditional Chinese medicine prescription in the experimental groups. The incidence rate of DVT are listed in Table [3](#Tab3){ref-type="table"}, the data of APTT and PT are in Table [4](#Tab4){ref-type="table"}, and the outcome of [d]{.smallcaps}-dimer is described in Table [5](#Tab5){ref-type="table"}. The date of subcutaneous hematoma is summarized in Table [6](#Tab6){ref-type="table"}.Table 1Basic characteristics assessment of included literaturesStudy yearCountrySurgery siteExperimental groupControl groupPrevention methodStudy quality*n*Male/femaleAge*n*Male/femaleAgeExperimental groupControl groupBi CQ 2009 \[[@CR12]\]ChinaFracture and arthroplasty3510\\2569.57 ± 9.84357\\2866.71 ± 9.13On the basis of the control group, Yiqi Poxue traditional Chinese medicineLow molecular weight heparin (LMWH)RCTChen CL 2014 \[[@CR13]\]ChinaArthroplasty4818\\3064.5 ± 15.64812\\3661.7 ± 12.5On the basis of the control group, Taohong Siwu soupRivaroxabanRCTChen T 2016 \[[@CR14]\]ChinaFracture4524\\2160.6 ± 1.84525\\2060.5 ±2.1On the basis of the control group, topical with traditional Chinese medicineLow molecular weight heparin (LMWH), aspirinRCTGe XL 2007 \[[@CR15]\]ChinaArthroplasty30--66.830--66.8On the basis of the control group, Ligustrazine hydrochlorideLow molecular weight heparin (LMWH)RCTHe Y 2013 \[[@CR16]\]ChinaArthroplasty62--6462--64On the basis of the control group, Yiqi Huoxue Huayu soupLow molecular weight heparin (LMWH)RCTHuang SX 2009 \[[@CR17]\]ChinaFracture and arthroplasty6035\\2558.66038\\2256.2On the basis of the control group, Danshen injection liquidLow molecular weight heparin (LMWH)RCTHuang XG 2010 \[[@CR18]\]ChinaArthroplasty3111\\2058.46329\\2355.72On the basis of the control group, Gubu soupLow molecular weight heparin (LMWH)RCTJiang KW 2011 \[[@CR19]\]ChinaArthroplasty65--66.473--66.4Chinese medicine decoctionLow molecular weight heparin (LMWH)RCTLi DF 2015 \[[@CR20]\]ChinaFracture and arthroplasty2516\\922--762518\\727--77On the basis of the control group, Huoxue Tongmai soupRivaroxabanRCTLi JH 2015 \[[@CR21]\]Chinafracture44--72±1741--68±18Danggui Shaoyao powderLow molecular weight heparin (LMWH)RCTLin X 2010 \[[@CR22]\]ChinaArthroplasty4025\\1578.15 ± 15.434026\\1476.36 ± 14.37Buyang Huanwu soupAspirinRCTShao ZH 2016 \[[@CR23]\]ChinaArthroplasty4524\\2167.4 ± 5.14523\\2266.6 ± 4.8On the basis of the control group, Danshen injection liquid, Taohong Siwu soupRivaroxabanRCTShi M 2011 \[[@CR24]\]ChinaArthroplasty2922\\769.13 ± 7.893423\\1167.49 ± 8.36Chinese medicine decoctionLow molecular weight heparin (LMWH)RCTWang XG 2017 \[[@CR25]\]ChinaFracture and arthroplasty3415\\1962.6 ± 5.813416\\1863.4 ± 3.17On the basis of the control group, Tongmai Yiqi Chinese medicine decoctionLow molecular weight heparin (LMWH)RCTXiao G 2015 \[[@CR26]\]ChinaFracture38----38----On the basis of the control group, Chinese medicine decoctionLow molecular weight heparin (LMWH)RCTYuan SH 2009 \[[@CR27]\]ChinaArthroplasty2816\\1266.42616\\1064.5On the basis of the control group, Shuxue Tongmai injection liquidLow molecular weight heparin (LMWH)RCTZhai JB 2016 \[[@CR28]\]ChinaFracture and arthroplasty3818\\2064.5 ± 10.23821\\1763.1 ± 10.8On the basis of the control group, Chinese medicine decoction self-madeLow molecular weight heparin (LMWH)RCTZhang FY 2009 \[[@CR29]\]ChinaFracture and arthroplasty4534\\11604230\\1256On the basis of the control group, Danshen injection liquidLow molecular weight heparin (LMWH)RCTZhao Q 2017 \[[@CR30]\]ChinaFracture9544\\5158.94 ± 7.029547\\4858.96 ± 4.93On the basis of the control group, Huoxue Zhuyu Tongluo soupLow molecular weight heparin (LMWH)RCTZhou ZQ 2010 \[[@CR31]\]ChinaFracture and arthroplasty7344\\2915--8510957\\5215--85Honghua injection liquidLow molecular weight heparin (LMWH)RCTTable 2The composition and efficacy of traditional Chinese medicine prescription in the experimental groupsFirst author and yearTraditional Chinese medicine compoundTreatment timeEffectBi CQ 2009 \[[@CR12]\]Huangqi 60 g, shuizhi 5 g, gancao 5 g, sanqi 3 gWater decoction, po, bid, 7 daysPromoting blood circulation to remove obstruction in the channelsChen CL 2014 \[[@CR13]\]Taohong siwu soup:taoren 10 g, honghua 10 g, danggui 12 g, chishuo 10 g, chuangxiong 6 g, dihuang 15 g, chuangshanjia 6 g, chaihu 12 g, huangqi 10 g, xiangfu 12 g, yanhusuo 15 g, xuduan 15 g, gancao 6 gWater decoction, po, bid, 7 daysPromoting blood by nourishing the bloodChen T 2016 \[[@CR14]\]Huajiao, sumu, mugua, shenjincao, danggui, niuxiWater decoction, hot pack, bidPromoting blood circulation to relieve painGe XL 2007 \[[@CR15]\]Yansuan chuanxiong injection 80 mgivgit, qd, 10 daysAntiplatelet agglutination, promoting blood circulation to remove obstruction in the channelsHe Y 2013 \[[@CR16]\]Yiqi huoxue huayu soup:dangshen 10 g, fuling 10 g, baishu 10 g, gancao 10 g, honghua 10 g, danggui 10 g, huangqi 10 g, taoren 10 g, shudi 6 g, chuanxiong 6 g, chishuo 6 g, zhike 6 g, jiegeng 6 g, dilong 3 gWater decoction, po, bid, po, 21 daysPromoting blood circulation to remove obstruction in the channelsHuang SX 2009 \[[@CR17]\]Danshen injection 20 ml and physiological saline 250 mlivgit, qd, 7 daysPromoting blood circulation to remove obstruction in the channelsHuang XG 2010 \[[@CR18]\]Gubu soup:huangqi 30 g, dangshen 30 g, jixueteng 30 g, danggui 15 g, danshen 30 g, chishuo 15 g, niuxi 15 g, baishu 15 g, yiren 20 g, huangbai 20 g, gancao 10 gWater decoction, po, bid, po, 9 daysPromoting blood circulation to remove obstruction in the channelsJiang KW 2011 \[[@CR19]\]Huangqi 30 g, shuizhi 3 g, sanqi 3 gWater decoction, po, bid, po, 7 daysPromoting blood circulation to remove obstruction in the channels, pain relief by diminishing swellingLi DF 2015 \[[@CR20]\]Huoxue tongmai soup:shuizhi 5 g, honghua 10 g, danggui 10 g, huangqi 20 g, danshen 10 g, fuling 10 g, yanhusuo 8 g, sanqi 6 gWater decoction, po, bid, po, 7 daysPromoting blood circulation to remove obstruction in the channelsLi JH 2015 \[[@CR21]\]Danggui shuoyao pills: danggui 3 g, chishuo 16 g, chuanxiong 8 g, fuling 4 g, zhexie 8 g, baishu 4 gWater pills,5 g/every time, po, qd, 7 daysPromoting blood by nourishing the blood, clearing heat, and removing dampnessLin X 2010 \[[@CR22]\]Buyang huanwu soup:sheng huangqi 30 g, dangguiwei 6 g, taoren 6 g, honghua 6 g, chuanxiong 9 g, chishuo 9 g, dilong 3 g, huainiuxi 9 gWater decoction, po, bid, po, 7 daysPromoting blood circulation to remove obstruction in the channelsShao ZH 2016 \[[@CR23]\]Danshen injection 20 ml, and 5% glucose injection; taohong siwu soup:honghua 10 g, taoren 15 g, danggui 15 g, chuanxiong 15 g, chishuoyao 15 g, niuxi 15 g, yinhuateng 20 g, yirenren 15 g, baishu 15 g, fuling 15 g, zhichuanwu 15 g, zhiruxiang 15 gDanshen injection:ivgit, qd; taohong siwu soup: water decoction, po, bidPromoting blood by nourishing the bloodShi M 2011 \[[@CR24]\]Shenghuangqi, dangguiwei, chishuo, dilong, chuanxiong, taoren, honghuaWater decoction, po, bid, po, 7 daysPromoting blood circulation to remove obstruction in the channels, pain relief by diminishing swellingWang XG 2017 \[[@CR25]\]Tongmaiyiqi soup:huangqi 15 g, baishu 15 g, quanxie 6 g, sanqi 6 g, shuizhi 6 g, zhexie 9 gWater decoction, po, bid, po, 14 daysPromoting blood circulation to remove obstruction in the channelsXiao G 2015 \[[@CR26]\]Huoxue tongmai soup:huangqi 30 g, niuxi 15 g, taoren 15 g, danshen 15 g, chishuo 15 g, shudi 15 g, chuanxiong 10 g, honghua 10 g, dangguiwei 10 g, shuizhi 5 gWater decoction, po, bid, po, 14 daysPromoting blood by nourishing the bloodYuan SH 2009 \[[@CR27]\]Shuxuetong injection 6 ml and 0.9% saline 250 mlivgit, qd, 15 daysPromoting blood circulation to remove obstruction in the channelsZhai JB 2016 \[[@CR28]\]Chuanxiong 10 g, shuizhi 5 g, honghua 15 g, dangshen 10 g, danggui 5 g, danshen 15 g, niuxi 15 gWater decoction, po, bid, po, 14 daysPromoting blood circulation to remove obstruction in the channels, pain relief by diminishing swellingZhang FY 2009 \[[@CR29]\]Danshen injection 20 mlIV, qd, 7 daysPromoting blood circulation to remove obstruction in the channelsZhao Q 2017 \[[@CR30]\]Huoxue zhuyu tongluo soup:dangguo 20 g, yirenren 5 g, danshen 10 g, shangzhi 5 g, tubie 5 g, sumu 10 g, chuanxiong 20 g, niuxi 3 gWater decoction, po, bid, po, 14 daysPromoting blood circulation to relieve painZhou ZQ 201031Honghua injection 20 ml and 0.9% saline 250 mlivgit, qd, 10 daysPromoting blood circulation to remove obstruction in the channelsTable 3Test data source and data extraction (incidence rate of DVT)First author and yearDVT diagnosisExperimental groupControl groupDVT siteBi CQ 2009 \[[@CR12]\]Color Doppler ultrasound0/35 (0.00%)1/35 (2.86%)Not mentionedChen CL 2014 \[[@CR13]\]Not mentioned1/48 (2.1%)4/48 8.3%Not mentionedChen T 2016 \[[@CR14]\]Not mentioned2/45 (4.44%)15/45 (33.33%)Not mentionedGe XL 2007 \[[@CR15]\]Color Doppler ultrasound, Angiography0/30 (0%)2/30 (6.67%)Distal thrombosis of the lower limbsHe Y 2013 \[[@CR16]\]Color Doppler ultrasound5/62 (8.1%)7/62 (11.3%)Not mentionedHuang SX 2009 \[[@CR17]\]Color Doppler ultrasound2/60 (3.3%)12/60 (20%)Not mentionedHuang XG 2010 \[[@CR18]\]Color Doppler ultrasound4/31(12.9%)7/32 (21.9%)Popliteal vein thrombosis 3 case, calf venous plexus 8 caseJiang KW 2011 \[[@CR19]\]Color Doppler ultrasound, Angiography12/65 (18%)8/73 (11%)Femoral vein thrombosis 1 case, popliteal vein thrombosis 1 case, gastrocnemius thrombosis 18 caseLi DF 2015 \[[@CR20]\]Not mentioned2/25 (8.0%)4/25 (16.0%)Not mentionedLi JH 2015 \[[@CR21]\]Color Doppler ultrasound1/44 (2.3%)6/41 (14.6%)Not mentionedLin X 2010 \[[@CR22]\]Color Doppler ultrasound4/40 (10.0%)10/40 (25.0%)Not mentionedShao ZH 2016 \[[@CR23]\]Color Doppler ultrasound1/45 (2.0%)6/45 (13.0%)Lower limb femoral veinShi M 2011 \[[@CR24]\]Color Doppler ultrasound0/29 (0%)0/34 (0%)Lower limb femoral veinWang XG 2017 \[[@CR25]\]Color Doppler ultrasound1/34 (2.94%)2/34 (5.88%)Not mentionedXiao G 2015 \[[@CR26]\]Not mentioned0/38 (0%)4/38 (10.53%)Not mentionedYuan SH 2009 \[[@CR27]\]Color Doppler ultrasound1/28 (3.57%)6/26 (23.07%)Not mentionedZhai JB 2016 \[[@CR28]\]Color Doppler ultrasound1/38(2.6%)6/38 (15.8%)Not mentionedZhang FY 2009 \[[@CR29]\]Color Doppler ultrasound4/45 (8.9%)7/42 (16.7%)Femoral vein thrombosis 7 case, popliteal vein thrombosis 4 caseZhao Q 2017 \[[@CR30]\]Color Doppler ultrasound9/95 (9.5%)26/95 (27.4%)Not mentionedZhou ZQ 2010 \[[@CR31]\]Color Doppler ultrasound5/73 (6.8%)11/109 (10.1%)Not mentionedTable 4Data source and data extraction (APTT and PT) of included studiesFirst author and yearPTAPTTExperimental groupControl groupExperimental groupControl group*n*Before the drugAfter the drug*n*Before the drugAfter the drugBefore the drug*n*After the drug*n*Before the drugAfter the drugHe Y 2013 \[[@CR16]\]6214.322 ± 0.96813.492 ± 0.8926214.102 ± 1.13213.321 ± 1.21138.902 ± 5.2326240.024 ± 6.2116240.101 ± 6.40340.883 ± 5.862Jiang KW 2011 \[[@CR19]\]6514.248 ± 0.98713.440 ± 0.7957314.037 ± 1.25013.277 ± 1.66138.862 ± 6.0156538.271 ± 3.9157341.797 ± 7.33341.171 ± 6.741Shao ZH 2016 \[[@CR23]\]4511.30 ± 1.6512.65 ± 1.564511.28 ± 1.5713.43 ± 1.3830.99 ± 4.634534.05 ± 4.924531.23 ± 4.3839.21 ± 5.28Shi M 2011 \[[@CR24]\]2913.504 ± 0.85713.925 ± 1.1433413.421 ± 1.00913.863 ± 0.97636.982 ± 4.5262936.334 ± 5.6133437.753 ± 6.66736.826 ± 4.761Wang XG 2017 \[[@CR25]\]3414.17 ± 0.7413.37 ± 0.833414.26 ± 0.8813.92 ± 0.5937.99 ± 8.023435.91 ± 6.953437.25 ± 6.4436.19 ± 7.93Xiao G 2015 \[[@CR26]\]3813.47 ± 1.2611.84 ± 0.633813.56 ± 1.5312.73 ± 1.4231.06 ± 5.873826.15 ± 4.183831.52 ± 6.0829.33 ± 5.27Zhao Q 2017 \[[@CR30]\]9510.08 ± 0.8914.98 ± 2.049510.06 ± 1.0412.72 ± 2.0720.14 ± 3.799537.89 ± 2.959520.56 ± 3.8029.69 ± 3.17Zhou ZQ 2010 \[[@CR31]\]7312.54 ± 1.0412.55 ± 1.410912.86 ± 1.1812.85 ± 1.4136.64 ± 4.357336.79 ± 4.6110937.65 ± 5.5638.01 ± 5.67Table 5Data source and data extraction ([d]{.smallcaps}-dimer) of included studiesFirst author and yearExperimental groupControl groupBefore the drug*n*After the drug*n*Before the drugAfter the drugBi CQ 2009 \[[@CR12]\]1.12 ± 1.11033350.6829 ± 0.4547350.74 ± 0.903650.72 ± 0.53292He Y 2013 \[[@CR16]\]1.242 ± 1.078620.792 ± 0.592620.832 ± 0.9120.792 ± 0.612Jiang KW 2011 \[[@CR19]\]1.120 ± 1.110650.682 ± 0.454730.740 ± 0.9030.720 ± 0.532Li JH 2015 \[[@CR21]\]0.856 ± 0.187440.509 ± 0.284410.791 ± 0.2210.693 ± 0.457Shao ZH 2016 \[[@CR23]\]0.154 ± 0.060451.405 ± 0.362450.142 ± 0.0511.968 ± 0.527Shi M 2011 \[[@CR24]\]0.986 ± 0.325290.603 ± 0.428340.962 ± 0.5470.891 ± 0.734Xiao G 2015 \[[@CR26]\]0.16 ± 0.09380.11 ± 0.26380.17 ± 0.100.16 ± 0.11Zhai JB 2016 \[[@CR28]\]1.525 ± 0.347381.642 ± 0.389381.493 ± 0.3212.205 ± 0.561Zhao Q 2017 \[[@CR30]\]1.90 ± 0.43951.65 ± 0.56951.90 ± 0.401.62 ± 0.62Table 6Data source and data extraction (subcutaneous hematoma) of included studiesFirst author and yearSubcutaneous hematomaExperimental groupControl groupBi CQ 2009 \[[@CR12]\]10/35 (28.57%)26/35 (74.29%)Jiang KW 2011 \[[@CR19]\]1/65 (2.2%)8/73 (17.8%)Li DF 2015 \[[@CR20]\]4/25 (8.9%)11/25 (44.0%)Li JH 2015 \[[@CR21]\]2/44 (4.5%)1/41 (2.4%)

Results of the meta-analysis {#Sec12}
----------------------------

In the eligible RCTs, all trials measured the incidence rate of DVT \[[@CR12]--[@CR31]\], while 8 trials reported the change of PT and APTT \[[@CR16], [@CR19], [@CR23]--[@CR26], [@CR30], [@CR31]\]. And 9 trials focused on the data of [d]{.smallcaps}-dimer \[[@CR12], [@CR16], [@CR19], [@CR21], [@CR23], [@CR24], [@CR26], [@CR28], [@CR30]\]. Besides, 4 RCTs \[[@CR12], [@CR19]--[@CR21]\] reported the incidence of subcutaneous hematoma.

### Comparison of the incidence of DVT between the two groups {#Sec13}

All 20 trials \[[@CR12]--[@CR31]\] involving 1862 patients measured the incidence rate of DVT, including 910 cases in the experimental groups and 952 cases in the control groups. There was a small degree of statistical heterogeneity across studies (*I*^2^ = 20%), and a fixed effects model was used for statistical analysis. The pooled analysis indicated that traditional Chinese medicine reduced the incidence rates of DVT significantly when compared with controls (risk ratio \[RR\] = 0.40; 95% CI, 0.30 to 0.54; *P* \< 0.00001) (Fig. [2](#Fig2){ref-type="fig"}).Fig. 2Effect of traditional Chinese and western medicine on the prevention in DVT

### PT, APTT, and [d]{.smallcaps}-dimer outcomes {#Sec14}

Eight trials \[[@CR16], [@CR19], [@CR23]--[@CR26], [@CR30], [@CR31]\] involving 931 patients measured PT and APTT, and nine trials \[[@CR12], [@CR16], [@CR19], [@CR21], [@CR23], [@CR24], [@CR26], [@CR28], [@CR30]\] involving 912 patients measured [d]{.smallcaps}-dimer. The random effects model was used for statistical analysis. The pooled analysis indicated that statistical heterogeneity was found among studies (PT: *I*^2^ = 92%, *P* \< 0.00001; APTT: *I*^2^ = 98%, *P* \< 0.00001; [d]{.smallcaps}-dimer: *I*^2^ = 83%, *P* \< 0.00001); the results showed there are no statistical difference of PT and APTT between the two groups (PT: MD = 0.01, 95% CI: − 0.56 to 0.58, *P* = 0.98, Fig. [3](#Fig3){ref-type="fig"}; APTT: MD = − 0.71, 95% CI: − 4.97 to 3.54, *P* = 0.74, Fig. [4](#Fig4){ref-type="fig"}). However, there is a statistical difference of [d]{.smallcaps}-dimer between the two groups ([d]{.smallcaps}-dimer: MD = − 0.18, 95% CI: − 0.32 to − 0.04, *P* = 0.01, Fig. [5](#Fig5){ref-type="fig"}).Fig. 3The effect on PT of two groupsFig. 4The effect on APTT of two groupsFig. 5The effect on [d]{.smallcaps}-dimer of two groups

### Subcutaneous hematoma {#Sec15}

Only 4 RCTs \[[@CR12], [@CR19]--[@CR21]\] involving 315 patients reported the incidence rate of subcutaneous hematoma. There was no statistical heterogeneity across studies (*I*^2^ = 21%), and a fixed effects model was used for statistical analysis. The pooled analysis indicated a significantly lower number of patients on experimental group undergoing the subcutaneous hematoma compared to that on the control group (risk ratio \[RR\] = 0.35; 95% CI, 0.22 to 0.56; *P* \< 0.00001) (Fig. [6](#Fig6){ref-type="fig"}).Fig. 6The incidence rate of subcutaneous hematoma in two groups

Quality assessment {#Sec16}
------------------

The quality assessment of the trials was performed using the Newcastle-Ottawa Scale. The detailed results are presented in Fig. [7](#Fig7){ref-type="fig"}. The overall quality of trials was moderate. Randomization was adequate in 20 trials (100%). All studies reported the similarity of study groups at baseline (100%). Outcome assessors blinded in 2 trials (10%), unclear in 18 trials (90%), the bias of blinding to patients in 2 trials (10%), unclear in 18 trials (90%). Allocation concealment and intention to treat items were difficult to assess from reported information.Fig. 7Risk of bias for RCTs

Discussion {#Sec17}
==========

DVT is a common complications after lower extremity orthopedic surgery, especially in THA, TKA, and hip fracture. The incidence of VTE is very high in patients who do not receive preventive anticoagulation therapy, some serious can develop into PE. The rescue success of fatal PE is extremely low and without any aura, which is one of the most common causes of non-expected death in the hospital. Therefore, the universality of DVT and the severity of PE after lower extremity orthopedic surgery have been formed into a consensus among doctors in different countries. Furthermore, lots of studies and guidelines have demonstrated that patients received lower extremity orthopedic surgery should begin preventive anticoagulation as soon as possible after ruled out any contraindications.

At present, the mechanical preventive measures of DVT includes graduated compression stocking (GCS), intermittent pneumatic compression devices (IPC), venous foot pump (VFP), early mobilization, and so on. However, the commonly used anticoagulant drugs, such as the unfractionated and warfarin from the last century to low molecular weight heparin (LMWH), and burgeonsing direct Xa factor inhibitors. Besides, the latest guidelines of AAOS also explicitly recommended aspirin as a drug for the prevention of DVT after lower extremity orthopedic surgery \[[@CR2]\].

For Chinese herbal medicine, also called traditional Chinese medicine, most western scholars may think that it is not a science, but an experience, and it is not supported by any theoretical foundation. However, in fact, using the traditional Chinese herbal medicine for prevention and treatment of thrombosis has been a thousand years of history in China; there is its own unique advantages. Promoting circulation and removing stasis and clearing heat and promoting diuresis are the main theory in the prevention and treatment of DVT \[[@CR32], [@CR33]\].

A total of 20 researched involving 1862 patients were included in our study; all papers are RCTs. The results of meta-analysis showed that traditional Chinese and western medicine therapy had obvious advantages in the prevention of DVT after lower extremity orthopedic surgery; the incidence rate of DVT was significantly lower than that of the control group with statistical difference. And the values of [d]{.smallcaps}-dimer was lower in the experimental group than those of the control group, with statistical difference. However, there was no statistical difference between PT and APTT in the two groups; it showed that traditional Chinese medicine did not increase the risk of bleeding or hemorrhage. Four RCTs described the incidence of subcutaneous hematoma after surgery; amazingly, meta-analysis indicated a significantly lower number of patients on the experimental group undergoing the subcutaneous hematoma compared to that in the control group, with statistical difference. In addition, there were no reports of any serious complications, demonstrating the safety of the combination of traditional Chinese and western medicine in the prevention of DVT.

Despite the lack of knowledge about the biological mechanisms of traditional Chinese medicine in the prevention of DVT, the synergy between the efficacy of Chinese herbal medicine and western medicine may play a major role in symptomatic treatment.

First, ingredients of traditional Chinese medicine can promote pain relief and flow of Qi (vital energy), reduce swelling and remove blood stasis, and bring more nutrients and oxygen to the healing tissues, so that blood circulation is improved and obstruction in the channels is removed \[[@CR34]\]. Second, researches have suggested that out-off-balance between the coagulation and anticoagulation system is a major reason to cause human body's hyperglycemia during the process of DVT formation. Third, traditional Chinese medicine theory studies have suggested that the basic pathogenesis of deep venous thrombosis is blood stasis in the meridians.

Some studies have already proved that traditional Chinese medicine has therapeutic efficacy in DVT. For example, Honghua \[[@CR35]\] injection has optimal therapeutic effect by its anti-thrombosis, anti-myocardial ischemia, microcirculation improvement, antioxidant, and other aspects. Danggui \[[@CR36]\] can expand blood vessels and inhibit platelet aggregation; besides, it also has the effect on anti-oxidation and free radical elimination. These benefits are largely dependent on its ingredients of polysaccharides, phthalates, coumarins, flavonoids, volatile oil compounds, and others. Chuanxiong \[[@CR37]\] has optimal therapeutic effect by its bio-activity such as anti-tumor, anti-inflammation, anti-apoptosis, and vasodilation. Danshen \[[@CR38]\] can prevent thrombosis by expanding the peripheral vessels and increasing the activity of plasmin. Some researches also indicated Danshen can exert its antithrombotic effect through inhibiting platelet aggregation (by increasing cAMP levels and inhibiting TXA2 synthesis in platelets) and improving the status of hemorheology property of the blood (by decreasing blood viscosity and shortening erythrocyte electrophoresis time).

These researches suggested that traditional Chinese medicine can eliminate obstruction in the channels for the patients with DVT by its effects on swelling alleviation, blood stasis removal, and blood circulation promotion. Cumulatively, these beneficial reports may cause the improvement of the clinical symptoms of deep venous thrombosis after lower extremity orthopedic surgery.

This is the first meta-analysis to evaluate the efficacy and safety of traditional Chinese and western medicine for the prevention of DVT after lower extremity orthopedic surgery, and all researches are RCTs to ensure the scientific reliability and rigor. But there are some limitations. First, the overall methodological quality of the RCTs was moderate. Many of the trials selected for inclusion contained some methodological deficiencies, so the number of truly high-quality studies eligible under these standards was too small. This might have caused bias. In the final results, some of the studies mentioned the word "random" but did not describe the specific method employed and did not mention whether a blind methodology was used or whether it had any dropout or not, which might cause a certain degree of bias risk. Second, all RCTs are unanimously published in Chinese academic journals due to the particularity of study contents, so we did not use statistical methods to test for publication bias. Third, some studies did not use the recommended guidelines for the prevention of DVT, and there is no explicit mention that if they conducted the evaluation of DVT after 11- to 35-day anticoagulant therapy in accordance with the guidelines. Besides, the definite location of thrombosis and whether there is some bleeding and other side effects were not mentioned. Therefore, we still need more large sample, high-quality, and multi-center RCTs to support the efficacy and safety of traditional Chinese and western medicine for the prevention of DVT after lower extremity orthopedic surgery.

Conclusion {#Sec18}
==========

Traditional Chinese medicine have the ability of swelling reduction and blood stasis removal, also can promote blood circulation to remove obstruction in the channels for patients. Cumulatively, these beneficial reports may result in reducing the incidence rate of DVT after lower extremity orthopedic surgery. Despite moderate quality of trials included and the existed bias of researches, Chinese traditional medicine therapy with a history dating back thousands of years radiates a glimmer of hope in the prevention of DVT after lower extremity orthopedic surgery. However, more high-quality, rigorously designed, and well-controlled RCTs are needed to support the clinical application of traditional Chinese medicine for the prevention of DVT.

APTT

:   Thromboplastin time

DVT

:   Deep venous thrombosis

GCS

:   Graduated compression stocking

HFS

:   Hip fracture surgery

IPC

:   Intermittent pneumatic compression devices

LMWH

:   Low molecular weight heparin

PE

:   Pulmonary embolism

PT

:   Prothrombin time

TCM

:   Traditional Chinese medicine

THR

:   Total hip replacement

TKR

:   Total knee replacement

VFP

:   Venous foot pump

VTE

:   Venous thromboembolism
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